WO2001049304A2 - Solutions ioniques aqueuses et leurs utilisations notamment en ophtalmologie - Google Patents

Solutions ioniques aqueuses et leurs utilisations notamment en ophtalmologie Download PDF

Info

Publication number
WO2001049304A2
WO2001049304A2 PCT/FR2000/003709 FR0003709W WO0149304A2 WO 2001049304 A2 WO2001049304 A2 WO 2001049304A2 FR 0003709 W FR0003709 W FR 0003709W WO 0149304 A2 WO0149304 A2 WO 0149304A2
Authority
WO
WIPO (PCT)
Prior art keywords
sea water
aqueous ionic
eye
hand
seawater
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2000/003709
Other languages
English (en)
French (fr)
Other versions
WO2001049304A3 (fr
Inventor
Jean-Claude Yvin
Bénédicte Marie Dominique HALLEY
Didier Leroy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Goemar SA
Original Assignee
Laboratoires Goemar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Goemar SA filed Critical Laboratoires Goemar SA
Priority to JP2001549672A priority Critical patent/JP2003519190A/ja
Priority to AU30295/01A priority patent/AU3029501A/en
Priority to CA2396045A priority patent/CA2396045C/fr
Priority to DE60035799T priority patent/DE60035799T2/de
Priority to EP00990830A priority patent/EP1242098B1/fr
Publication of WO2001049304A2 publication Critical patent/WO2001049304A2/fr
Publication of WO2001049304A3 publication Critical patent/WO2001049304A3/fr
Anticipated expiration legal-status Critical
Priority to US11/135,113 priority patent/US7700077B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/08—Mineral waters; Sea water
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the invention relates to aqueous ionic solutions of the kind which are obtained in particular from sea water and their uses, in particular in ophthalmology.
  • aqueous ionic solutions are new.
  • the invention therefore targets them as new industrial products.
  • aqueous ionic solutions obtained from seawater are known.
  • the subject of the invention is therefore the use for the treatment and hygiene of the eye and its annexes of the aqueous ionic solutions obtained from sea water and whose ionic composition, pH and osmolality have been adapted accordingly.
  • the ionic composition of the solutions used in accordance with the invention is that of seawater.
  • the composition of seawater as shown in the table below is indicated. 'it appears on page F 163 of the book "Handbook of Chemistry and Physics” 63rd edition, 1982-1983, CRC PRESS. BOARD
  • the ionic composition of the solutions in question obtained from sea water is chosen such that their pH is from 4 to 9, preferably from 7 to 8 and that their osmolality is from 150 to 700, preferably 250 to 350 mOsm / kg.
  • aqueous ionic solutions obtained by dilution of sea water, in particular with distilled water, in particular at the rate of 2 5 times
  • - aqueous ionic solutions obtained from sea water by techniques known as desalting and, optionally, enriched in at least one of their ions
  • aqueous ionic solutions obtained artificially from salts sailors are characterized by:
  • - for Mg from 50 to 1300, preferably from 100 to 500 mg / 1, - for Ca ++ , from 20 to 350, preferably from 40 to 200 mg / 1,
  • the new aqueous ionic solutions in accordance with the invention are particularly suitable for the treatment and hygiene of the eye and its annexes.
  • aqueous ionic solutions in accordance with the invention when they are used in the treatments and hygiene of the eye and its annexes, are remarkable in that they have the pH and the physiological osmolality of the tears, and that they are free of preservatives. This last advantage is of great importance. Indeed, the preservatives present in most eye medications are considered to be harmful to the cornea.
  • sea water was used drawn off Saint-Malo and sampled at a depth of 5 to 10 meters in an area with strong movements. current ; this water is characterized by a salt content greater than 32 g / 1; it is naturally rich in calcium, magnesium and trace elements.
  • This water is subjected to a selective electrodialysis; firstly, only the sodium chloride is removed to achieve the desired osmolality, then the ionic concentrations are adjusted according to the therapeutic use; the desired pH is preferably obtained by exchanging the ions
  • Selective electrodialysis can be carried out with a device of the EUR 6B type marketed by the company EURODIA Industrie SA under the brand EURODIA.
  • the Draize test makes it possible to assess eye irritation after multiple applications; it can be used on the eye of the albino rabbit.
  • the reference solution used in this test is constituted, as indicated above, by physiological saline, that is to say by a sodium chloride solution (0.9% NaCl); physiological saline is traditionally used to rinse the eyes in the event of accidental chemical projection, to clean the eyes of infants and also as a solvent for artificial tears, as eye drops or as an ophthalmic washing solution; it's here reference solution in ophthalmology for the French Agency for the Sanitary Safety of Health Products.
  • 12 albino rabbits are divided into two groups (a reference group and a group for the solution tested).
  • 50 ⁇ l of physiological saline is administered six times in succession at 1 hour intervals in the conjunctival cul-de-sac of the right eye, on the one hand, and on the other hand , 50 ⁇ l of the solution tested in the case of rabbits from the other group.
  • the intensity (e) of the opacity is evaluated, knowing that the note 0 is attributed to the absence of opacity and the note 4 to a total corneal opacity. with invisible iris and, on the other hand, the surface of the opacities (f), the notes going from 0 to 4, this last note corresponding to an opacification of more than% of the total surface.
  • the arithmetic mean of the values found for the 6 rabbits represents the average eye irritation index (MOI).
  • the maximum eye irritation index (MOI max) is the maximum individual value obtained with each measurement.
  • Day 1/1 denotes the measurement made 1 hour after the instillation era
  • Day 1/6 denotes the measurement made 1 hour after the 6th instillation
  • Day 2 indicates the measurement made 24 hours after the last instillation
  • Day 3 indicates the measurement made 48 hours after the last instillation
  • Day 4 indicates the measurement made 72 hours after the last instillation.
  • the products, in particular ophthalmic, prepared by using aqueous ionic solutions according to the invention or more generally all aqueous ionic solutions obtained from sea water can be presented, for example, in the form of lotions intended for washing the eye, in the form of eye drops, ophthalmic gels or to replace water in the ocular inserts.
  • composition of such a lotion can be as follows: - Aqueous ionic solution: q.s. 100%
  • the lotions in question can be administered using more preferably devices of the type of those according to the French patent application filed in the name of the Applicant on October 13, 1999 under No. 99 12782 under the title "Device for washing and bathing of the eye ".

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/FR2000/003709 1999-12-31 2000-12-28 Solutions ioniques aqueuses et leurs utilisations notamment en ophtalmologie Ceased WO2001049304A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2001549672A JP2003519190A (ja) 1999-12-31 2000-12-28 水性イオン性溶液及び、特に眼科学におけるその使用
AU30295/01A AU3029501A (en) 1999-12-31 2000-12-28 Aqueous ionic solutions and their uses in particular in ophthalmology
CA2396045A CA2396045C (fr) 1999-12-31 2000-12-28 Solutions ioniques aqueuses et leurs utilisations notamment en ophtalmologie
DE60035799T DE60035799T2 (de) 1999-12-31 2000-12-28 Ionische wässrige lösungen und deren verwendungen insbesondere in der ophtalmologie
EP00990830A EP1242098B1 (fr) 1999-12-31 2000-12-28 Solutions ioniques aqueuses et leurs utilisations notamment en ophtalmologie
US11/135,113 US7700077B2 (en) 1999-12-31 2005-05-23 Aqueous ionic solutions and their uses in particular in ophthalmology

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR99/16814 1999-12-31
FR9916814A FR2803205B1 (fr) 1999-12-31 1999-12-31 Solutions ioniques aqueuses et leurs utilisations notamment en ophtalmologie

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10169284 A-371-Of-International 2000-12-28
US11/135,113 Continuation US7700077B2 (en) 1999-12-31 2005-05-23 Aqueous ionic solutions and their uses in particular in ophthalmology

Publications (2)

Publication Number Publication Date
WO2001049304A2 true WO2001049304A2 (fr) 2001-07-12
WO2001049304A3 WO2001049304A3 (fr) 2002-05-23

Family

ID=9554118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/003709 Ceased WO2001049304A2 (fr) 1999-12-31 2000-12-28 Solutions ioniques aqueuses et leurs utilisations notamment en ophtalmologie

Country Status (10)

Country Link
US (2) US20030152645A1 (enExample)
EP (1) EP1242098B1 (enExample)
JP (1) JP2003519190A (enExample)
AT (1) ATE368468T1 (enExample)
AU (1) AU3029501A (enExample)
CA (1) CA2396045C (enExample)
DE (1) DE60035799T2 (enExample)
FR (1) FR2803205B1 (enExample)
PT (1) PT1242098E (enExample)
WO (1) WO2001049304A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1417970A3 (en) * 2002-11-06 2004-07-07 Farmaceutici S.R.L. Anti-allergic, anti-bacteric and anti-redden compound for eyes
CN103340901A (zh) * 2013-07-17 2013-10-09 银川高新区广煜科技有限公司 纯天然成分的眼药水及其制备和使用方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2843029B1 (fr) * 2002-08-02 2006-05-26 Goemar Lab Sa Solution de rincage pour lentilles de contact
FR2872046B1 (fr) * 2004-06-28 2006-09-15 Pascal Hemmery Compostion a base d'eau de mer, son procede de preparation, son utilisation pour l'hygiene de l'appareil genital feminin et dispositif pour son utilisation
FR2905267B1 (fr) * 2006-09-05 2012-02-17 Yslab Solution a ionisation controlee a base d'eau de mer, destine a l'ophtalmologie.
FR2915389B1 (fr) * 2007-04-26 2012-12-21 De La Mer Laboratoire Utilisation de solutions ioniques isoosmotiques a base d'eau de mer pour la fabrication de dispositifs medicaux pour la prevention des complications du rhume courant
FR2971713B1 (fr) 2011-02-18 2019-03-29 Laboratoire De La Mer Solution ionique aqueuse contenant de l'eau de mer et au moins un compose originellement non miscible a l'eau de mer.
FR3005264B1 (fr) * 2013-05-03 2015-05-15 Ys Lab Solution marine enrichie en zinc et en potassium
IT201600078342A1 (it) * 2016-07-26 2018-01-26 Farm S R L C U S Processo per la ristrutturazione idroionica delle acque termali e marine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581226A (en) * 1983-04-07 1986-04-08 Dillon Richard S Method of treating sensitive animal tissue with a specially processed seawater solution
FR2735980B1 (fr) * 1995-06-30 1997-09-12 Sun Trading Ltd Nouvelles preparations pour l'otologie et leur procede de preparation
FR2778562B1 (fr) * 1998-05-14 2000-08-04 Sephra Composition pharmaceutique, hygienique et/ou cosmetique contenant de l'eau de mer et de l'arginine
FR2780284B1 (fr) * 1998-06-29 2001-10-05 Goemar Lab Sa Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments cerumenolytiques a base de ces solutions
FR2780285B1 (fr) * 1998-06-29 2001-10-05 Goemar Lab Sa Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments anti-inflammatoires a base de ces solutions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1417970A3 (en) * 2002-11-06 2004-07-07 Farmaceutici S.R.L. Anti-allergic, anti-bacteric and anti-redden compound for eyes
CN103340901A (zh) * 2013-07-17 2013-10-09 银川高新区广煜科技有限公司 纯天然成分的眼药水及其制备和使用方法

Also Published As

Publication number Publication date
JP2003519190A (ja) 2003-06-17
US7700077B2 (en) 2010-04-20
FR2803205B1 (fr) 2002-10-18
US20030152645A1 (en) 2003-08-14
CA2396045C (fr) 2010-09-21
US20060003025A1 (en) 2006-01-05
DE60035799D1 (de) 2007-09-13
DE60035799T2 (de) 2008-04-30
EP1242098B1 (fr) 2007-08-01
ATE368468T1 (de) 2007-08-15
EP1242098A2 (fr) 2002-09-25
WO2001049304A3 (fr) 2002-05-23
AU3029501A (en) 2001-07-16
PT1242098E (pt) 2007-10-31
CA2396045A1 (fr) 2001-07-12
FR2803205A1 (fr) 2001-07-06

Similar Documents

Publication Publication Date Title
US5866142A (en) Skin treatment system
CN87104644A (zh) 广谱杀病毒剂
EP0193416A1 (fr) Composition aseptisante pour lentilles de contact
FR2560523A1 (fr) Solution ophtalmique contenant du pranoprofene et de l'acide borique
EP0484199B1 (fr) Utilisation cosmétique d'une composition ayant une activité anti-érythémale
EP1196185B1 (fr) Nouvelle utilisation de solutions salines hypoosmotiques et medicament a base de ces solutions
EP1242098A2 (fr) Solutions ioniques aqueuses et leurs utilisations notamment en ophtalmologie
JP2020128437A (ja) シリコーンハイドロゲルコンタクトレンズ用眼科組成物
US11484483B2 (en) Topical lotion having sanitizing properties
PT93244B (pt) Processo de preparacao de composicoes pediculicidas a base de piperonal
FR2521856A1 (fr) Medicament ophtalmique pour le traitement des glaucomes, a base d'ethers-oxydes ou d'ether-oximes de derives alcoylamines
EP0035919A2 (fr) Composition pour le traitement des cheveux
DE69932922T2 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
JP2018127449A (ja) 光及びポリカルボン酸を使用して皮膚疾患を治療するための組成物及び方法
KR20070079582A (ko) 치료상의 처리를 향상시키는 피부 처리 방법
WO2008037938A1 (fr) Solutions ioniques hypertoniques a base d'eau de mer non diluee, leur utilisation en tant que compositions pharmaceutiques ou medicaments et pour la preparation de medicaments destines au traitement de la congestion nasale
US6726922B1 (en) Process and composition for temporarily suppressing pain
JP2015078235A (ja) シリコーンハイドロゲルコンタクトレンズ用点眼剤
FR2518882A1 (fr) Composition therapeutique, a base de monophosphate d'inosine, pour le traitement des troubles d'accommodation de l'oeil
FR2591890A1 (fr) Composition a usage therapeutique comprenant des composes organo-silicies
JP2981602B2 (ja) フコイダンを配合した脱臭洗浄剤。
EP0067084B1 (fr) Composition pour collyre destiné au traitement des conjonctivités et kératites
FR2661091A1 (fr) Utilisation de l'hexetidine ou de ses derives ou sels pour la preparation d'une composition pharmaceutique a usage ophtalmologique.
JPH05262639A (ja) 洗浄剤組成物
EP3280394B1 (fr) Gel a base de sel et son utilisation dans la prévention et le traitement des parasitoses et des affections dermatologiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000990830

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2396045

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 549672

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000990830

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10169284

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2000990830

Country of ref document: EP